H. Lundbeck A/S
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HLUBF research report →
About the company
H. Lundbeck A/S engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders. Its product portfolio targets the following diseases: Alzheimer's, depression, Parkinson's, Schizophrenia, alcohol dependence, anxiety, bipolar disorder, epilepsy, and Huntington's.
- CEO
- Charl van Zyl
- IPO
- 2022
- Employees
- 5,127
- HQ
- Valby, DK
Price Chart
- Market Cap
- $5.84B
- P/E
- 11.58
- P/S
- 1.36
- P/B
- 1.67
- EV/EBITDA
- 5.54
- Div Yield
- 2.67%
- Gross Margin
- 78.95%
- Op Margin
- 27.86%
- Net Margin
- 14.71%
- ROE
- 14.81%
- ROIC
- 11.62%
- Revenue
- $24.30B · 10.42%
- Net Income
- $3.18B · 1.33%
- EPS
- $3.21 · 1.26%
- Op Income
- $6.33B
- FCF YoY
- 56.98%
- 52W High
- $6.41
- 52W Low
- $3.70
- 50D MA
- $5.39
- 200D MA
- $5.41
- Beta
- 0.26
- Avg Volume
- 36
Get TickerSpark's AI analysis on HLUBF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our HLUBF coverage
Recent articles, reports, and earnings notes.
No research on HLUBF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HLUBF report →Similar companies
Peers in the same neighborhood.